DEBORAH MILES: Open Payments
NPI 1245200468 · PARAGOULD, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$996 in 26 payments from 10 companies in 2025. Trend: 2023 $1,175 · 2024 $671 · 2025 $996
Food & beverage: $996
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $235 |
| AstraZeneca Pharmaceuticals LP | 5 | $218 |
| Otsuka America Pharmaceutical, Inc. | 7 | $153 |
| ABBVIE INC. | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $92 |
| Lilly USA, LLC | 1 | $90 |
| Axsome Therapeutics, Inc. | 1 | $38 |
| GlaxoSmithKline, LLC. | 2 | $30 |
| Amgen Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $3 |
Products named: AIRSUPRA, REXULTI, Wegovy, QULIPTA, CAPLYTA, ZEPBOUND, Ozempic, Auvelity.
Industry payments across AR — which companies pay providers there.
